The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...

Patients found to have positive lymph nodes after robotic radical cystectomy for muscle-invasive bladder cancer may benefit from treatment de-escalation if they have undetectable circulating tumor DNA ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license ...

Early radical cystectomy can be beneficial and should be performed in patients with refractory T1 tumors or carcinoma in situ before progression to muscle invasion. In this Review I present an ...

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...

Opens in a new tab or window Bladder-preserving trimodality therapy may be a potential alternative to radical cystectomy in patients with high-grade T1 bladder cancer that has progressed despite ...

Discover a study comparing two types of treatment for bladder cancer, robot-assisted radical cystectomy and intracorporeal ...

Ferring activates first sites in a three-arm study of ADSTILADRIN as a monotherapy or in combination with chemotherapy or an ...

The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...

Three-stage (group 2) 10 3.68 ± 0.55 Unilateral only 3.4 (MD) NS, baseline vs follow-up; NS group 1 vs 2 OE, prior cystectomy (group 2) 112 Not reported but all <6 cm 19.60 7.9 ± 4.2 Tubal ...

US FDA grants priority review status to AstraZeneca’s sBLA for Imfinzi to treat patients with muscle-invasive bladder cancer: Cambridge, UK Saturday, December 7, 2024, 09:00 Hrs ...

At ESMO 2024, Dr. Andrea Necchi presented the results of an interim analysis of SunRISe-4, noting a pathological complete response rate in the combination arm of 42% and pathologic objective response ...